Development of a new therapeutic strategy for cardiomyopathy by administration of mRNA

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461135
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Nara Medical University
• Principal Investigator: Onoue Kenji 奈良県立医科大学, 医学部, 助教 (90510173)
• Co-Investigator(Renkei-kenkyūsha): Kataoka Kazunori 東京大学, 工学研究科, 教授 (00130245) ; Itaka Keiji 東京大学, 医学系研究科, 准教授 (60292926)
• Research Collaborator: Wakimoto Hiroko ハーバード大学, 遺伝学部門, 講師
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 循環器 / 心筋症 / 遺伝学

Outline of Final Research Achievements

The pathology of idiopathic dilated cardiomyopathy had been gradually elucidated in terms of genetic or molecular mechanisms. However, the treatment for that is still palliative in medication or mechanical support. In this study, we aimed for establish a new causal treatment by administrating a messenger RNA (mRNA) of mutationally deficient protein to a mouse model of dilated cardiomyopathy. It took much longer time than we expected for the biosynthesis of mRNA and the determination of a way of the most effective administration of that. We finally established those in 2 years and are currently working on experiments in which we can evaluate the effectiveness of this new causal treatment.

Free Research Field

循環器